NCT05684588

Brief Summary

During the most recent pandemy COVID-19, various advises concerning complications following high corticosteroid doses administration were pubblished in 2020. However, evidence is lacking about the incidence of Non-traumatic osteonecrosis of the femoral head (ONFH) in patients experiencing COVID-19. The aim of the present proposal is to obtain a quantitative estimation of ONFH cases among patients previoulsy hospitalized and treated for COVID-19 at ASST-Papa Giovanni XXIII.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2021

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 11, 2021

Completed
4 days until next milestone

Study Start

First participant enrolled

November 15, 2021

Completed
1.2 years until next milestone

First Posted

Study publicly available on registry

January 13, 2023

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 10, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 10, 2023

Completed
Last Updated

February 23, 2024

Status Verified

February 1, 2024

Enrollment Period

1.9 years

First QC Date

November 11, 2021

Last Update Submit

February 22, 2024

Conditions

Keywords

Femoral osteonecrosisCorticosteroidsCOVID-19

Outcome Measures

Primary Outcomes (1)

  • Number of patients with femoral osteonecrosis

    Number of patients showing osteonecrotic lesions

    1 year after previous hospitalization

Secondary Outcomes (6)

  • Description of patients clinical features

    hospitalization time 89 days

  • Description of COVID-19

    hospitalization time 89 days

  • Description of therapies employed during hospitalization

    hospitalization time 89 days

  • Definition of the stage of ONFH cases

    1 year after previous hospitalization

  • Number of all ON types that will be detected

    1 year after previous hospitalization

  • +1 more secondary outcomes

Study Arms (1)

Instrumental diagnostic evaluation

OTHER

After enrollment all patients will undergo an instrumental evaluation including a radiography (according to clinical practice) and a magnetic resonance (experimental procedure outside clinical practice), at 1 year from previous hospitalization

Diagnostic Test: Magnetic Resonance

Interventions

Magnetic ResonanceDIAGNOSTIC_TEST

After enrollment a Magnetic Resonance without medium contrast, at 1 year from previous hospitalization

Instrumental diagnostic evaluation

Eligibility Criteria

Age18 Years - 59 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Male
  • Age \> 18 and \< 60 years old
  • Hospitalization between 23-Feb-2020 and 21-May-2020 because of COVID-19 diagnosis
  • Hospitalization duration \> 25 days
  • Treatment with steroid drugs during hospitalization (total cumulative dose \> 2 g)
  • Signature of written informed consent

You may not qualify if:

  • Presence of any implantable medical device defined as 'unsafe' for RM (eg. Cardiac pacemaker; vascular stent and gastrointestinal clips evaluated as 'unsafe')
  • Previous experience with episodes and symptoms associated with claustrophobia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

ASST-Papa Giovanni XXIII

Bergamo, Lombardy, 24127, Italy

Location

MeSH Terms

Conditions

OsteonecrosisCOVID-19

Interventions

Magnetic Resonance Imaging

Condition Hierarchy (Ancestors)

Bone DiseasesMusculoskeletal DiseasesNecrosisPathologic ProcessesPathological Conditions, Signs and SymptomsPneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

TomographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosis

Study Officials

  • Claudio Ca Castelli, Prof

    FROM-Fondazione per la Ricerca Ospedale di Bergamo

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Model Details: This is an experimental (non-pharmacological) diagnostic, pilot and monocentric study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 11, 2021

First Posted

January 13, 2023

Study Start

November 15, 2021

Primary Completion

October 10, 2023

Study Completion

October 10, 2023

Last Updated

February 23, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations